Vanda [VNDA] vs Cg Oncology [CGON] Detailed Stock Comparison
Vanda
NASDAQ
Loading...
Cg Oncology
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Vanda wins in 9 metrics, Cg Oncology wins in 7 metrics, with 0 ties. Vanda appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Vanda | Cg Oncology | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 126.00 | -18.23 | Cg Oncology |
| Price-to-Book Ratio | 0.53 | 2.92 | Vanda |
| Debt-to-Equity Ratio | 2.39 | 0.15 | Cg Oncology |
| PEG Ratio | 21.80 | -0.20 | Cg Oncology |
| EV/EBITDA | 0.61 | -8.27 | Cg Oncology |
| Profit Margin (TTM) | -32.90% | 0.00% | Cg Oncology |
| Operating Margin (TTM) | -73.21% | -28,546.10% | Vanda |
| Return on Equity | -13.01% | -12.00% | Cg Oncology |
| Return on Assets (TTM) | -9.88% | -11.66% | Vanda |
| Free Cash Flow (TTM) | $-16.25M | $-78.95M | Vanda |
| 1-Year Return | -16.15% | -24.90% | Vanda |
| Price-to-Sales Ratio (TTM) | 1.27 | 3,556.38 | Vanda |
| Enterprise Value | $-56.28M | $1.30B | Cg Oncology |
| EV/Revenue Ratio | -0.28 | 2,358.45 | Vanda |
| Gross Profit Margin (TTM) | 94.80% | N/A | N/A |
| Revenue per Share (TTM) | $3 | $0 | Vanda |
| Earnings per Share (Diluted) | $-1.14 | $-1.78 | Vanda |
| Beta (Stock Volatility) | 0.73 | N/A | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Vanda vs Cg Oncology Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Vanda | -1.58% | 3.81% | -8.40% | 10.94% | -2.24% | -9.54% |
| Cg Oncology | -1.00% | 3.42% | 3.01% | 1.38% | -6.10% | -11.29% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Vanda | -16.15% | -57.87% | -59.10% | -61.95% | -32.61% | -55.05% |
| Cg Oncology | -24.90% | -26.63% | -26.63% | -26.63% | -26.63% | -26.63% |
Performance & Financial Health Analysis: Vanda vs Cg Oncology
| Metric | VNDA | CGON |
|---|---|---|
| Market Information | ||
| Market Cap | $257.63M | $1.96B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 486,410 | 688,770 |
| 90 Day Avg. Volume | 534,930 | 908,667 |
| Last Close | $4.36 | $25.70 |
| 52 Week Range | $3.81 - $5.55 | $14.80 - $40.47 |
| % from 52W High | -21.44% | -36.50% |
| All-Time High | $33.44 (Dec 03, 2018) | $50.23 (Feb 12, 2024) |
| % from All-Time High | -86.96% | -48.84% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.04% | -1.00% |
| Quarterly Earnings Growth | 0.04% | -1.00% |
| Financial Health | ||
| Profit Margin (TTM) | -0.33% | 0.00% |
| Operating Margin (TTM) | -0.73% | -285.46% |
| Return on Equity (TTM) | -0.13% | -0.12% |
| Debt to Equity (MRQ) | 2.39 | 0.15 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $8.23 | $8.79 |
| Cash per Share (MRQ) | $5.51 | $8.67 |
| Operating Cash Flow (TTM) | $-64,797,000 | $-93,817,000 |
| Levered Free Cash Flow (TTM) | $-38,860,376 | $396.48M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Vanda vs Cg Oncology
| Metric | VNDA | CGON |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 126.00 | -18.23 |
| Forward P/E | 21.80 | -14.44 |
| PEG Ratio | 21.80 | -0.20 |
| Price to Sales (TTM) | 1.27 | 3,556.38 |
| Price to Book (MRQ) | 0.53 | 2.92 |
| Market Capitalization | ||
| Market Capitalization | $257.63M | $1.96B |
| Enterprise Value | $-56,283,392 | $1.30B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | -0.28 | 2,358.45 |
| Enterprise to EBITDA | 0.61 | -8.27 |
| Risk & Other Metrics | ||
| Beta | 0.73 | N/A |
| Book Value per Share (MRQ) | $8.23 | $8.79 |
Financial Statements Comparison: Vanda vs Cg Oncology
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | VNDA | CGON |
|---|---|---|
| Revenue/Sales | $50.04M | $52,000 |
| Cost of Goods Sold | $3.52M | N/A |
| Gross Profit | $46.52M | N/A |
| Research & Development | $35.71M | $27.47M |
| Operating Income (EBIT) | $-41.03M | $-42.20M |
| EBITDA | $-39.05M | $-42.18M |
| Pre-Tax Income | $-37.37M | $-34.45M |
| Income Tax | $-7.87M | N/A |
| Net Income (Profit) | $-29.49M | $-34.45M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | VNDA | CGON |
|---|---|---|
| Cash & Equivalents | $111.80M | $41.47M |
| Total Current Assets | $407.91M | $701.19M |
| Total Current Liabilities | $103.92M | $22.64M |
| Long-Term Debt | $7.35M | $781,000 |
| Total Shareholders Equity | $511.42M | $704.76M |
| Retained Earnings | $-203.79M | $-252.43M |
| Property, Plant & Equipment | $12.48M | $1.30M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | VNDA | CGON |
|---|---|---|
| Operating Cash Flow | $-27.01M | $-28.85M |
| Capital Expenditures | $-436,000 | $-16,000 |
| Free Cash Flow | $-33.58M | $-29.29M |
| Debt Repayment | $-409,000 | $0 |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | VNDA | CGON |
|---|---|---|
| Shares Short | 4.53M | 11.00M |
| Short Ratio | 8.86 | 11.27 |
| Short % of Float | 0.08% | 0.15% |
| Average Daily Volume (10 Day) | 486,410 | 688,770 |
| Average Daily Volume (90 Day) | 534,930 | 908,667 |
| Shares Outstanding | 58.31M | 76.15M |
| Float Shares | 49.48M | 61.15M |
| % Held by Insiders | 0.07% | 0.01% |
| % Held by Institutions | 0.79% | 1.12% |
Dividend Analysis & Yield Comparison: Vanda vs Cg Oncology
| Metric | VNDA | CGON |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |